A draft interim policy published by the Department of Health and Human Services on Oct. 30 covers six experimental peptides and signals that regulators do not intend to pursue enforcement against qualifying compounders who follow a set of conditions. Muscle & Fitness, reporting on the notice, is blunt that this is not the same thing as approving six new drugs.
The six compounds named are BPC-157, TB-500, KPV, MOTS-c, epitalon and Semax. Compounding is when a licensed professional prepares a medication for an individual patient rather than dispensing a mass-produced approved product, and the proposed policy calls for patient-specific prescriptions, traceable ingredients, quality documentation and reporting of serious adverse events.
What the notice does not do
It does not authorize supplement companies to put these compounds into pre-workouts, and it does not establish that any product is safe or effective. The federal notice is open for public comment, the policy can be revisited if safety or quality problems emerge, and state-level rules still apply on top of it.
Anyone announcing that peptides have been FDA approved, as the piece puts it, has either misunderstood the document or is counting on you not reading it. That distinction is the whole story here, and it is the one most likely to get lost in the next round of marketing emails.
Where the evidence stops
FDA scientists raised concerns about the lack of convincing clinical data and about product safety. An advisory committee nevertheless supported broader compounding access for the six substances, which tells you the experts disagree, not that either side has settled anything.
The article is candid that clinical evidence in humans for the sweeping claims made about BPC-157 and TB-500 is thin. A cleaner supply chain is not the same as a molecule that has been shown to work, and that is the most useful sentence in the piece.
The anti-doping problem
BPC-157 and TB-500 remain prohibited under World Anti-Doping Agency rules used by many tested sports. A shift in how federal regulators view compounding does not rewrite the WADA rulebook, and a prescription is not automatically permission to compete with a substance in your system.
USADA has already sanctioned athletes over these compounds. Some banned peptides can be detected directly in urine or blood, while others present a much tougher analytical problem, and WADA does not need a routine test in place before it bans something.
Bottom line
Three questions are being conflated: whether something is easier to obtain, whether it has been shown to be worth obtaining, and whether using it ends a career in a tested sport. The draft only touches the first.
Comments (0)
Discussion happens on Reddit.
Go to r/PeptideNewsroomQuestions and corrections go to r/PeptideNewsroom.